Atomoxetine 10 mg, 18 mg and 40 mg: Supply issue

Supply issue Active

Arrotex Pharmaceuticals advise that there may be supply issues with atomoxetine caps 10 mg, 18 mg and 40 mg presentations.

18 mg Alternative version listed 10 June 2021

We are listing an Eli Lilly product on the Schedule to ensure atomoxetine remains available. The alternative product is Medsafe-approved.

Note: Strattera will not appear on the Schedule until 1 July 2021. It will be fully funded from 10 June 2021.

Affected product

  • Cap 18 mg | Pharmacode 2566834 | $27.06 per 28

Listed alternative product

  • Cap 18 mg | Pharmacode 2181576 | Brand: Strattera

Note: Ministry of Health Sector Operations Group will not be able to process claims for June 2021 dispensing of the above listing. Pharmacies can either:

  • hold these claims until July 2021 
  • reclaim them in July 2021 when they are rejected for payment in June 2021 claims.

10 and 40 mg alternative version listed 1 April 2021

We are listing an Eli Lilly product on the Schedule to ensure atomoxetine remains available. The alternative product is Medsafe-approved.

Affected product

  • Cap 10 mg | Pharmacode 2566826 | $18.41 per 28
  • Cap 40 mg | Pharmacode 2566826 | $29.22 per 28

Listed alternative product

  • Cap 10 mg | Pharmacode 2181568 | Brand: Strattera  
  • Cap 40 mg | Pharmacode 2181592 | Brand: Strattera 

Who to contact

If you take atomoxetine, talk to your pharmacist or prescriber. They know you best. PHARMAC cannot give clinical advice on any individual person.

If you have questions about supply, contact Arrotex or your wholesaler.

If you have questions about funding for atomoxetine, email us on enquiry@pharmac.govt.nz